268. Nakajo-Nishimura syndrome Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 2 Drugs : 3 - (DrugBank : 1) / Drug target genes : 2 - Drug target pathways : 37

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)
Baricitinib
   Eli Lilly and Company
      2020   Phase 2/Phase 3   NCT04517253   Japan
      -   Phase 2;Phase 3   EUCTR2025-000001-16-Outside-EU/EEA   Japan
LY3009104
   Eli Lilly and Company
      -   Phase 2;Phase 3   EUCTR2025-000001-16-Outside-EU/EEA   Japan
Olumiant
   Eli Lilly and Company
      -   Phase 2;Phase 3   EUCTR2025-000001-16-Outside-EU/EEA   Japan